Ulcerative Colitis - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Ulcerative Colitis - Pipeline Review, H2 2013 market report to its offering
Ulcerative Colitis - Pipeline Review, H2 2013


, 'Ulcerative Colitis - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ulcerative Colitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcerative Colitis. Ulcerative Colitis - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Ulcerative Colitis.
- A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ulcerative Colitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Bristol-Myers Squibb Company
Johnson & Johnson
Amgen Inc.
AstraZeneca PLC
Athersys, Inc.
GlaxoSmithKline plc
Genentech, Inc.
MedImmune LLC
Gilead Sciences, Inc.
Euroscreen S.A.
Takeda Pharmaceutical Company Limited
BioLineRx, Ltd.
Celltrion, Inc.
Axcan Pharma Inc.
Biocon Limited
Pfizer Inc.
Sigma-Tau S.p.A.
GW Pharmaceuticals plc
Hollis-Eden Pharmaceuticals, Inc.
iCo Therapeutics Inc.
Karo Bio
Ore Pharmaceuticals Inc
Cosmo Pharmaceuticals S.p.A
Lexicon Pharmaceuticals, Inc.
LTT Bio-Pharma Co., Ltd.
Galapagos NV
InDex Pharmaceuticals AB
Am-Pharma B.V.
Upsher-Smith Laboratories, Inc.
Palau Pharma S.A
Farmacija d.o.o. Tuzla
Hutchison MediPharma Limited
Viropro Inc.
Tillotts Pharma AG
Coronado Biosciences, Inc.
Amalyte Pharmaceuticals, LLC
GP Pharm, S.A.
Vascular Biogenics Ltd.
TcL Pharma SAS
Avaxia Biologics, Inc.
Drais Pharmaceuticals, Inc.
Giuliani S.p.A.
Synergy Pharmaceuticals, Inc.
Medestea Research & Production S.p.A.
NasVax Ltd.
Antibe Therapeutics, Inc.
Dr. Falk Pharma GmbH
Flexion Therapeutics
Receptos, Inc.
Altheus Therapeutics, Inc.
AesRx, LLC.
Atlantic Healthcare Limited
Sigmoid Pharma.

To view the table of contents for this market research report please visit